Tyra Biosciences (TYRA) Free Cash Flow (2020 - 2026)

Tyra Biosciences has reported Free Cash Flow for 7 years, with the latest figure at -$32.6 million in Q1 2026.

• For the quarter ending Q1 2026, Free Cash Flow fell 27.95% year-over-year to -$32.6 million; the trailing twelve-month figure through Mar 2026 stood at -$102.3 million (down 40.02% YoY), and the FY2025 full-year result was -$95.2 million, down 36.45% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$32.6 million, down from -$23.7 million in the prior quarter.
• The five-year high for Free Cash Flow was -$9.2 million in Q1 2022, with the low at -$32.6 million in Q1 2026.
• Historically, Free Cash Flow has averaged -$17.5 million across 5 years, with a median of -$17.2 million in 2023.
• Annual changes were most pronounced in 2022 — Free Cash Flow slumped 274.6% — and 2023, when it soared 43.05%.
• Tyra Biosciences' Free Cash Flow stood at -$12.0 million in 2022, then dropped by 12.69% to -$13.5 million in 2023, then tumbled by 40.34% to -$18.9 million in 2024, then declined by 25.01% to -$23.7 million in 2025, then sank by 37.71% to -$32.6 million in 2026.
• The last three Free Cash Flow figures came in at -$32.6 million (Q1 2026), -$23.7 million (Q4 2025), and -$22.4 million (Q3 2025), per Business Quant data.